Aktis Oncology (AKTS) CMO discloses multiple stock option grants

Rhea-AI Filing Summary

Aktis Oncology, Inc. Chief Medical Officer Akos Czibere filed an initial ownership report showing holdings of several stock options. These options give rights to buy common stock at exercise prices of $4.95 for 271,218 shares, $9.33 for 98,570 shares, $11.46 for 19,714 shares, and $18.00 for 131,426 shares, all held directly. Portions of the earlier grants vested on July 1, 2025 and October 9, 2025, with the remaining shares vesting in equal monthly installments, subject to continued service. Newer grants are scheduled to begin vesting with 25% cliffs on November 1, 2026 and January 8, 2027, followed by monthly vesting thereafter.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Czibere Akos

(Last) (First) (Middle)

C/O AKTIS ONCOLOGY, INC.

17 DRYDOCK AVENUE, SUITE 17-401

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2026

3. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	06/30/2034	Common Stock	271,218	$4.95	D
Stock Option (Right to Buy)	(2)	10/10/2034	Common Stock	98,570	$9.33	D
Stock Option (Right to Buy)	(3)	12/11/2035	Common Stock	19,714	$11.46	D
Stock Option (Right to Buy)	(4)	01/07/2036	Common Stock	131,426	$18	D

Explanation of Responses:

1. 25% of the original number of shares subject to the option vested on July 1, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

2. 25% of the original number of shares subject to the option vested on October 9, 2025, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

3. 25% of the original number of shares subject to the option shall vest on November 1, 2026, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

4. 25% of the original number of shares subject to the option shall vest on January 8, 2027, and 1/48th of the original number of shares subject to the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Akos Czibere	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 3 filing show for Aktis Oncology (AKTS)?

It shows that Chief Medical Officer Akos Czibere beneficially owns several stock options giving rights to purchase common stock at set exercise prices, all reported as directly held.

How many Aktis Oncology stock options does Akos Czibere hold?

He holds stock options for 271,218, 98,570, 19,714, and 131,426 shares of Aktis Oncology, Inc. common stock, each reported as a separate grant.

What are the exercise prices of the reported Aktis Oncology (AKTS) options?

The options reported have exercise prices of $4.95, $9.33, $11.46, and $18.00 per share of common stock.

When do the Aktis Oncology options held by the CMO vest?

For the first two grants, 25% vested on July 1, 2025 and October 9, 2025, with the rest vesting in equal monthly installments. For the later grants, 25% vests on November 1, 2026 and January 8, 2027, with remaining shares vesting monthly thereafter, all subject to continuous service.

Are the reported Aktis Oncology (AKTS) options held directly or indirectly?

All of the stock options listed in the filing are reported as held in direct ownership by Akos Czibere.

What role does the reporting person have at Aktis Oncology (AKTS)?

The reporting person, Akos Czibere, is an officer of Aktis Oncology, Inc. serving as Chief Medical Officer and is not reported as a director or 10% owner.